EU GMP focus will shift from post- to pre-approval review under MRA, Glaxo's Hitchings predicts.
Executive Summary
EU INSPECTION FOCUS WILL SHIFT TO PRE-APPROVAL GMPs UNDER MRA, GLAXO predicted June 24 at the Drug Information Association annual meeting in Montreal. As a result of the Good Manufacturing Practices Mutual Recognition Agreement signed by the U.S. and the European Union June 20, "what we would anticipate is the European focus changing a bit from post-approval GMP to pre-approval," Glaxo Wellcome (U.K.) Director-Group Quality William Hitchings said. "We're looking to see greater consistency between the inspecting agencies on that standpoint."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth